Table 13.

CXCL8-CXCR1/2 axis blockade for cancer therapy

Classification	Products	NCT number	Cancer types	Combination partners	Phase	Status
Anti-CXCL8 mAb	HuMax-IL8	NCT02536469	Solid Tumor	Monotherapy	I	Completed
		NCT03689699	Prostate Cancer	Nivolumab and Degarelix	I/II	Active, not recruiting
		NCT04848116	HNSCC	Nivolumab	II	Recruiting
		NCT02451982	Pancreatic Cancer	Nivolumab	II	Recruiting
CXCR1/2i	SX-682	NCT05604560	Pancreatic Cancer	Tislelizumab	II	Recruiting
		NCT06228053	mCRPC	Enzalutamide	II	Not yet recruiting
		NCT04574583	Solid Tumors	M7824, MVA-BN-CV301, and FPV-CV301	I/II	Active, not recruiting
		NCT06149481	Colorectal Cancer	Retifanlimab, TriAdeno Vaccine, and N-803	I/II	Not yet recruiting
		NCT04599140	Colorectal Cancer	Nivolumab	I/II	Recruiting
		NCT05570825	NSCLC	Pembrolizumab	II	Recruiting
		NCT04477343	Pancreatic Cancer	Nivolumab	I	Recruiting
		NCT03161431	Melanoma	Pembrolizumab	I	Recruiting
	Ladarixin	NCT05815186	NSCLC With KRAS G12C Mutation	Sotorasib	II	Withdrawn
		NCT05815173	NSCLC With KRAS G12C Mutation	Sotorasib	I	Recruiting
Selective CXCR1i	Reparixin	NCT01861054	Breast Cancer	Monotherapy	II	Terminated
		NCT02001974	Breast Cancer	Paclitaxel	I	Completed
		NCT02370238	Breast Cancer	Paclitaxel	II	Completed
		NCT05212701	Breast Cancer	Monotherapy	II	Withdrawn
Selective CXCR2i	AZD5069	NCT03177187	mCRPC	Enzalutamide	I/II	Terminated
		NCT02499328	Solid Tumors	MEDI4736 and Tremelimumab	I/II	Active, not recruiting
		NCT02583477	Pancreatic Cancer	MEDI4736	I/II	Completed
	Navarixin	NCT03473925	Solid Tumors	Pembrolizumab	II	Completed

Note: HNSCC head and neck squamous cell carcinoma, mCRPC metastatic castration-resistant prostate cancer, NSCLC non-small cell lung cancer